Standout Papers

Gastroenteropancreatic neuroendocrine tumours 1996 2026 2006 2016 1.2k
  1. Gastroenteropancreatic neuroendocrine tumours (2008)
    Irvin M. Modlin, Kjell Öberg et al. The Lancet Oncology
  2. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system (2006)
    Guido Rindi, G. Klöppel et al. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  3. Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival (2008)
    Dik J. Kwekkeboom, Wouter W. de Herder et al. Journal of Clinical Oncology
  4. Octreotide (1996)
    Steven W. J. Lamberts, Aart‐Jan van der Lely et al. New England Journal of Medicine
  5. Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors (2005)
    Dik J. Kwekkeboom, Jaap J.M. Teunissen et al. Journal of Clinical Oncology
  6. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms (2022)
    Guido Rindi, Özgür Mete et al. Endocrine Pathology
  7. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors (2017)
    Tessa Brabander, Wouter A. van der Zwan et al. Clinical Cancer Research
  8. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms (2016)
    Gianfranco Delle Fave, Dermot O’Toole et al. Neuroendocrinology
  9. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024)
    Simron Singh, Daniel Halperin et al. The Lancet

Immediate Impact

2 by Nobel laureates 20 from Science/Nature 81 standout
Sub-graph 1 of 18

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
2022 Standout
20 intermediate papers

Works of Wouter W. de Herder being referenced

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
2017 Standout
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
2008 Standout
and 17 more

Author Peers

Author Last Decade Papers Cites
Wouter W. de Herder 15448 12572 10324 404 23.2k
Éric Baudin 8735 7994 5655 338 19.6k
Kjell Öberg 20253 17885 14309 385 25.7k
Eric P. Krenning 14150 12260 9088 268 22.0k
Aurel Perren 9518 9051 5707 257 15.2k
Philippe Ruszniewski 15010 17154 9243 421 22.2k
Günter Klöppel 12151 18600 5098 448 29.0k
Manisha H. Shah 4700 7500 3000 198 17.4k
Richard A. Feelders 4738 3308 3183 260 12.0k
Larry K. Kvols 9971 9006 7210 213 13.5k
Henning Dralle 5891 4552 2311 579 26.0k

All Works

Loading papers...

Rankless by CCL
2026